Regulation of thyroid hormone binding to its cytosolic binding protein by L-alpha-alanine

Allosteric regulation of metabolism in cancer: endogenous mechanisms and considerations for drug design

Alterations in metabolic processes have been linked to various diseases, including cancer. Although gene expression can dictate long-term metabolic adaptation, many metabolic changes found in cancer are associated with altered allosteric properties of the underlying enzymes. Small molecule-protein interactions and intracellular signalling converge to orchestrate these allosteric mechanisms, which, emerging evidence suggests, constitute a promising therapeutic avenue. In this review we focus on glucose and energy metabolism to illustrate the role of allostery in cancer physiology and we discuss approaches to streamline the process of targeting aberrant allosteric pathways with small molecules.

Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulator

Pyruvate kinase activity is controlled by a tightly woven regulatory network. The oncofetal isoform of pyruvate kinase (PKM2) is a master regulator of cancer metabolism. PKM2 engages in parallel, feed-forward, positive and negative feedback control contributing to cancer progression. Besides its metabolic role, non-metabolic functions of PKM2 as protein kinase and transcriptional coactivator for c-MYC and hypoxia-inducible factor 1-alpha are essential for epidermal growth factor receptor activation-induced tumorigenesis. These biochemical activities are controlled by a shift in the oligomeric state of PKM2 that includes acetylation, oxidation, phosphorylation, prolyl hydroxylation and sumoylation. Metabolically active PKM2 tetramer is allosterically regulated and responds to nutritional and stress signals. Metabolically inactive PKM2 dimer is imported into the nucleus and can function as protein kinase stimulating transcription. A systems biology approach to PKM2 at the genome, transcriptome, proteome, metabolome and fluxome level reveals how differences in biomolecular structure translate into a global rewiring of cancer metabolism. Cancer systems biology takes us beyond the Warburg effect, opening unprecedented therapeutic opportunities.

Synthesis of thyroid hormone binding proteins transthyretin and albumin by human trophoblast

CONTEXT

Mechanisms regulating materno-fetal transfer of thyroid hormone are not well understood. Modulation of trophoblast type 3 iodothyronine deiodinase (D3) may play an important role.

OBJECTIVE

The objective of this study was to investigate trophoblast thyroid hormone binding proteins that may modulate interactions between D3 and T4.

DESIGN

Placentas were obtained by informed consent from women delivering normal infants by repeat cesarean section at 38-40 wk gestation. T4 and T3 binding was examined in human placenta. Serum thyroid hormone binding proteins were identified by Western blotting, and their mRNA was examined by RT-PCR. Presence of these proteins in trophoblast was determined by immunocytochemistry and immunofluorescence. Cytosol was progressively purified to reveal additional thyroid hormone binding proteins that were identified by matrix-assisted laser desorption/ionization time of flight mass spectrometry. Effects of mefenamic acid on placental deiodination were examined by HPLC.

RESULTS

We detected high-affinity T4 and T3 binding in human placental cytosol. All three major serum-binding proteins, T4 binding globulin (TBG), transthyretin (TTR), and albumin, were present in cytosol. TTR mRNA and albumin mRNA were detected in human placenta, and TTR and albumin were identified histochemically in syncytiotrophoblasts. Neither TBG mRNA nor TBG was detected, suggesting that plasma TBG had contaminated the cytosol preparation. Low-affinity thyroid hormone binding proteins alpha-1-antitrypsin and alpha-1-acid glycoprotein were also identified. Addition of mefenamic acid, a potent inhibitor of thyroid hormone binding, to placental cytosol significantly enhanced deiodination of T4 by D3.

CONCLUSIONS

Placenta produces a series of thyroid hormone binding proteins that may modify thyroid hormone deiodination and materno-fetal thyroid hormone transport.

Requisite structural characteristics for benzodiazepine inhibition of triiodothyronine uptake into a human liver cell line

Previously, we reported potent inhibition of triiodo-L-thyronine (T3) cellular uptake into a human liver cell line (HepG2) by central and peripheral receptor specific benzodiazepine (BZ) compounds and our working hypothesis of BZ's as direct competitors for the iodothyronine transporter, displacing T3 but not acting as a substrate for transport. In this report, we list other reported uptake inhibitors and compare them to 23 benzodiazepine receptor ligands, in their potency to inhibit cellular uptake of T3. The most potent inhibitors are restricted to the benzodiazepine class. From the BZ structure-activity relationship (SAR) for inhibition, we see that the nonfused phenyl ring may be essential for activity and the strongest relationship is seen with substitution at R2' where Cl greater than F greater than H. Substitution at R4' and hydroxyl substitution at R3 enhances potency as will alkyl groups at R1 or on the imidazole group in the 1,2-annelated series. With R7 substitution, Cl is preferred over NO2 but not necessarily H when R4' = Cl; this may reflect a slightly different orientation of the molecule with large aliphatic R1 groups and/or R4' substitution. The carbonyl at R2 in the 1,4 benzodiazepine series, enhances their potency. The resultant structure-activity relationship highlights the importance of the halogen-substituted nonfused phenyl ring and seems unique relative to other described benzodiazepine sites and/or effects.